BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26

• Drug Development

  Avaxia Biologics, Inc. Receives FDA Orphan Drug Designation For AVX-470 For The Treatment Of Pediatric Ulcerative Colitis

  November 21, 2014

   · 

  3 min read
• Biotech Beach

  WCCT Global Announced As Finalist For Contract Research Organization Of 2014

  November 21, 2014

   · 

  2 min read
• Deals

  Collagen Solutions To Acquire Leading NZ Based Providers Of Medical Grade Collagen For £6 Million

  November 21, 2014

   · 

  2 min read
• Business

  Agilent Technologies Inc. Names Patrick Kaltenbach, Jacob Thaysen Business Group Presidents; New Organization Designed To Support Customers, Growth

  November 21, 2014

   · 

  4 min read
• Drug Development

  Relypsa, Inc. Announces Data Published In The New England Journal of Medicine For Pivotal Phase 3 Program Of Patiromer FOS For The Treatment Of Hyperkalemia

  November 21, 2014

   · 

  7 min read
• Business

  Tandem Diabetes Care Announces Partnership With Tidepool To Further Expand Access To Diabetes Device Data

  November 21, 2014

   · 

  3 min read
• Drug Development

  ChemoCentryx, Inc.'s CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA

  November 21, 2014

   · 

  5 min read
• Drug Development

  Immunomedics, Inc. Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus

  November 21, 2014

   · 

  5 min read
• Business

  Dehaier Medical Systems Ltd. And WideMed Ltd. Broaden And Extend Exclusive Strategic Partnership For Six More Years

  November 21, 2014

   · 

  4 min read
• Biotech Bay

  FDA Accepts IDE Supplement For Cerus Corporation’s INTERCEPT Blood System Treatment Of Ebola Convalescent Plasma

  November 21, 2014

   · 

  6 min read